Top in endocrinology: Endocrine-disrupting chemicals in kids; mini-insulin pump update

Children exposed to higher levels of certain endocrine-disrupting chemicals in utero were more likely to develop metabolic syndrome than those who were not, according to findings published in JAMA Network Open.

Researchers used data from a population-based birth cohort to assess associations between metabolic syndrome risk score and prenatal exposure to mixtures of endocrine-disrupting chemicals (EDCs). They concluded that exposure to higher levels of prenatal metals, organochlorine pesticides, polybrominated diphenyl ethers and perfluoroalkyl and polyfluoroalkyl substances were linked to higher risk scores.

“These results underscore the importance of reducing exposure to EDC mixtures during pregnancy to safeguard children’s metabolic health and address the increasing prevalence of metabolic syndrome across the life course,” Nuria Güil-Oumrait, MSc, a predoctoral researcher at Barcelona Institute for Global Health in Spain, told Healio.

It was the top story in endocrinology last week.

In another top story, a miniature-sized automated insulin delivery system that received FDA clearance in 2023 is now compatible with a new-generation continuous glucose monitor.

Read these and more top stories in endocrinology below:

Prenatal exposure to EDCs may increase metabolic syndrome risk for children

Children exposed in utero to higher levels of some types of endocrine-disrupting chemicals have a higher risk for developing metabolic syndrome, data show. Read more.

Miniature-sized insulin pump now compatible with two CGM systems

A miniature-sized automated insulin delivery system cleared by the FDA in 2023 is now compatible with a new-generation continuous glucose monitor, according to a press release. Read more.

Diabetes does not raise risk for subsequent hip fracture after incident fracture

Older adults with type 1 or type 2 diabetes who sustain an incident hip fracture have a similar likelihood for a subsequent hip fracture as those without diabetes, according to study data published in Bone. Read more.

New vitamin D consensus guideline, debates highlight ENDO annual meeting

Endocrinology providers and researchers gathered in Boston on June 1 as the Endocrine Society held its 2024 annual meeting. Read more.

Vosoritide boosts annual height velocity with multiple genetic causes of short stature

Vosoritide was associated with increased annualized height velocity for children with five different genetic causes of short stature, according to study findings. Read more.